BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/22/2021 8:09:41 AM | Browse: 662 | Download: 1818
 |
Received |
|
2021-05-28 21:01 |
 |
Peer-Review Started |
|
2021-05-28 21:04 |
 |
First Decision by Editorial Office Director |
|
2021-07-06 01:57 |
 |
Return for Revision |
|
2021-07-06 01:57 |
 |
Revised |
|
2021-07-15 16:24 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2021-08-11 03:25 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2021-08-11 06:48 |
 |
Articles in Press |
|
2021-08-11 06:48 |
 |
Edit the Manuscript by Language Editor |
|
2021-08-24 04:29 |
 |
Typeset the Manuscript |
|
2021-09-17 02:59 |
 |
Publish the Manuscript Online |
|
2021-09-22 08:09 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
COVID-19 and non-alcoholic fatty liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Francesco Bellanti and Gianluigi Vendemiale |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Francesco Bellanti, MD, PhD, Doctor, Doctor, Research Associate, Teaching Assistant, Department of Medical and Surgical Sciences, University of Foggia, Viale Pinto, 1, Foggia 71122, Italy. francesco.bellanti@unifg.it |
| Key Words |
Non-alcoholic fatty liver disease; Metabolic-associated fatty liver disease; COVID-19; SARS-CoV-2; Liver injury; Immune dysregulation |
| Core Tip |
Non-alcoholic fatty liver disease (NAFLD) is the most widespread hepatic disorder. Recently re-named as metabolic-associated fatty liver disease (MAFLD), it has been lately pointed out as a predisposing factor for severe coronavirus disease 2019 (COVID-19). We herein discuss the epidemiology and possible underlying pathways predisposing severe COVID-19 in NAFLD/MAFLD patients. |
| Publish Date |
2021-09-22 08:09 |
| Citation |
Bellanti F, Vendemiale G. COVID-19 and non-alcoholic fatty liver disease. World J Hepatol 2021; 13(9): 969-978 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i9/969.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i9.969 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.